Aurobindo Pharma arm receives USFDA nod for Triamcinolone Acetonide injectable suspension

Aurobindo Pharma arm receives USFDA nod for Triamcinolone Acetonide injectable suspension

By, Admin 7 July 2022

Aurobindo said the approved product has an estimated market size of around USD 73 million for the 12 months ended May 2022. Aurobindo Pharma Ltd on Wednesday said its arm, Eugia Pharma Specialities Ltd, has received a final approval from the US health regulator to manufacture and market Triamcinolone Acetonide injectable suspension indicated for various conditions, including allergies and rheumatoid arthritis. The approval by the US Food & Drug Administration (USFDA) is for Triamcinolone Acetonide injectable suspension for strengths of 200 mg/5 ml and 400 mg/10 ml, multiple dose vials, the company said. The product is being launched this month, it added. It is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company's reference listed drug Kenalog-40 injectable suspension, 40 mg/ml, the company said. Citing IQVIA data, Aurobindo said the approved product has an estimated market size of around USD 73 million for the 12 months ended May 2022. Aurobindo said this is the 142nd abbreviated new drug application, including 8 tentative approvals received, out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!